Status:
UNKNOWN
DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening
Lead Sponsor:
Lei Li
Collaborating Sponsors:
Obstetrics & Gynecology Hospital of Fudan University
The Third Xiangya Hospital of Central South University
Conditions:
Endometrial Cancer
Cancer Screening
Eligibility:
FEMALE
18+ years
Brief Summary
Based on the previous study of NCT04651738, we performed this trial to further confirm the accuracy of host DNA CDO1 and CELF4 methylation for endometrial cancer screening. This study would provide pr...
Eligibility Criteria
Inclusion
- With uerine and uterine cervix intact
- Aged 18 years or older
- With accessible histological results of endometrium
- Signed an approved informed consents
- With accessible cervical cytology before harvesting endometrial histology
Exclusion
- Not meeting all of the inclusion criteria
Key Trial Info
Start Date :
March 12 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 12 2023
Estimated Enrollment :
7150 Patients enrolled
Trial Details
Trial ID
NCT05290922
Start Date
March 12 2022
End Date
March 12 2023
Last Update
March 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730